二庚基乙酸乙酯 | 63905-75-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 二庚基乙酸乙酯
• 英文名称: Pentadecancarbonsaeureaethylester-8
• 英文别名: 2-heptyl-nonanoic acid ethyl ester；2-Heptyl-nonansaeure-aethylester；ethyl 2-heptylnonanoate
• CAS: 63905-75-9
• 化学式: C₁₈H₃₆O₂
• 分子量: 284.483
• InChiKey: XRCJOMAARACHTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  20
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2915900090

反应信息

• 作为产物：
  描述：

  乙醇 、 2-heptyl-nonanoic acid 在 盐酸 、 calcium chloride 作用下， 生成 二庚基乙酸乙酯
  参考文献：
  名称：

  Some Isomeric Branched Hexadecanols

  摘要：

  DOI：

  10.1021/ja01313a014

文献信息

• [EN] PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS<br/>[FR] PYRIDINE-2-AMIDES UTILES COMME AGONISTES DE CB2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014086805A1

  公开（公告）日：2014-06-12

  The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.

  这项发明涉及一种化合物，其化学式为（I），其中R1至R4的定义如描述和索赔中所述。化合物的化学式（I）是一种CB2激动剂，可用作药物的活性成分。
• Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof
  申请人：FRICK Wendelin

  公开号：US20110059910A1

  公开（公告）日：2011-03-10

  The invention relates to substituted aromatic fluoroglycoside derivatives, and to the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to methods of lowering blood sugar and the treatment of type I and type II diabetes.

  这项发明涉及取代芳香族氟糖苷衍生物，以及其生理兼容盐和生理功能衍生物。该发明还涉及降低血糖和治疗I型和II型糖尿病的方法。
• [EN] TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE TETRAHYDRO-ISOQUINOLYL-ACETAMIDE DESTINES A SERVIR D'ANTAGONISTES DES RECEPTEURS D'OREXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004085403A1

  公开（公告）日：2004-10-07

  The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.

  该发明涉及公式（I）的新型乙酰胺衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备这类化合物的方法、含有其中一个或多个这类化合物的药物组合物，特别是它们作为促进睡眠的药物受体拮抗剂的用途。
• [EN] IRIDIUM COMPLEX AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME<br/>[FR] COMPLEXE D'IRIDIUM ET DISPOSITIF PHOTOÉMETTEUR ORGANIQUE L'INCLUANT
  申请人：CANON KK

  公开号：WO2014115528A1

  公开（公告）日：2014-07-31

  The present invention provides a novel iridium complex and an organic light-emitting device including the novel iridium complex. The novel iridium complex includes three ligands, and two of them have a phenyl-naphtho[2,1-f]isoquinoline skeleton. The present invention also provides a display apparatus including the organic light-emitting device and an electrophotographic image-forming apparatus including a light source including the organic light-emitting device and including a photosensitive member.

  本发明提供了一种新型铱配合物和包括该新型铱配合物的有机发光器件。该新型铱配合物包括三个配体，其中两个具有苯基-萘并[2,1-f]异喹啉骨架。本发明还提供了包括该有机发光器件的显示装置，以及包括包括该有机发光器件的光源和包括感光成员的静电成像形成装置。
• THROMBIN INHIBITORS
  申请人：——

  公开号：US20010007764A1

  公开（公告）日：2001-07-12

  The invention relates to non-slow-binding thrombin inhibitors of the formula: A-B-C-Lys-D wherein A is H, 2 -hydroxy- 3 -cyclohexyl-propionyl-, R 1 , R 1 —O—CO—, R 1 —SO 2 —, —(CHR 2 ) n COOR 3 , or an N-protecting group, wherein R 1 is selected from -( 1 - 6 C)alkylene-COOH, ( 1 - 12 C)alkenyl, ( 6 - 14 C)aryl, ( 7 - 15 C)aralkyl and ( 8 - 16 C)aralkenyl, the group of which may be substituted with ( 1 - 6 C)alkyl, ( 2 - 12 C)alkoxy, hydroxy, or halogen; R 2 is H or has the same meaning as R 1 , R 3 is selected from H, ( 1 12 C)alkyl, ( 2 - 12 C)alkenyl, ( 6 - 14 C)aryl, ( 7 - 15 C)aralkyl and ( 8 - 16 C)aralkenyl, the aryl group of which may be substituted with ( 1 - 6 C)alkyl, ( 2 - 12 C)alkoxy, hydroxy or halogen; n is an integer of 1 to 3 ; B is a bond, L-Asp or an derivative thereof, Leu,norLeu, -n(benzyl)—CH 2 —CO—, -N( 2 -indane)—CH 2 —CO—, D- 1 Piq, D-Tiq, Atc or a D-amino acid having a hydrophobic aromatic side chain; C is Azt, Pro, Pec, norLeu(cyclo)Gly, an amino acid of one of the formulae -N[( 3 - 8 C)cycloalkyl]—CH—CO—or -N(benzyl)—CH 2 —CO —, D is selected from COOH, tetrazole, oxazole,thiazole and benzothiazole, or A znd C have the aforesaid meaning, B is D-( 3 - 8 C) cycloalkylalanine, and D is tetrazole, oxazole, thiazole or benzothiazole; or a prodrug thereof; or a pharmaceutically acceptable salt thereof; with the exception of the compound Me-D-Phe-Pro-Lys-COOH. The compounds can be used as antithrombotic agents.

  该发明涉及公式为：A-B-C-Lys-D的非缓慢结合的凝血酶抑制剂，其中A为H，2-羟基-3-环己基-丙酰-，R1，R1—O—CO—，R1—SO2—，—(CHR2)nCOOR3，或者N-保护基，其中R1选自-(1-6C)烷基-COOH，(1-12C)烯基，(6-14C)芳基，(7-15C)芳基烷基和(8-16C)芳基烯基，该基团可能被(1-6C)烷基，(2-12C)烷氧基，羟基或卤素取代；R2为H或具有与R1相同的含义，R3选自H，(1-12C)烷基，(2-12C)烯基，(6-14C)芳基，(7-15C)芳基烷基和(8-16C)芳基烯基，芳基可能被(1-6C)烷基，(2-12C)烷氧基，羟基或卤素取代；n为1到3的整数；B为键，L-天冬氨酸或其衍生物，亮，norLeu，-n(苄基)—CH2—CO—，-N(2-茚)—CH2—CO—，D-1Piq，D-Tiq，Atc或具有疏水芳香侧链的D-氨基酸；C为Azt，Pro，Pec，norLeu(cyclo)Gly，其中一种氨基酸的公式为-N[(3-8C)环烷基]—CH—CO—或-N(苄基)—CH2—CO—，D从COOH，四唑，噁唑，噻唑和苯并噻唑中选择，或A和C具有上述含义，B为D-(3-8C)环烷基丙氨酸，D为四唑，噁唑，噻唑或苯并噻唑；或其前药；或其药学上可接受的盐；除了化合物Me-D-Phe-Pro-Lys-COOH之外。这些化合物可用作抗血栓药物。